CDC Surveillance for Respiratory Syncytial Virus (RSV) and Other Viral Respiratory Infections among Native Americans/Alaska Natives
RFA-IP-19-001

Grants.gov  https://www.grants.gov/web/grants/view-opportunity.html?oppId=308248

Limited to one application per institution

If you wish to apply to a program that limits the number of applications allowed per institution, please email a one-page abstract about your proposal with a link to the program of interest to Cheryl Ridgeway cheryl-a-ridgeway@uiowa.edu  in the Office of the Vice President for Research and Economic Development with a cc to the Division of Sponsored Programs  dsp@uiowa.edu   at least 30 days in advance of the deadline.  If we receive multiple abstracts in response to a given solicitation, a review will be conducted to select the applicant to submit on behalf of the University of Iowa.

Respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory tract infection including bronchiolitis and pneumonia in infants and children worldwide. The annual rate of RSV hospitalizations for children less than 2 years of age in the US is 5.2 per 1,000, but substantially higher among Native Americans. There are currently approximately 40 vaccines or antibody products in development designed to prevent RSV infections. With potential licensure of these products on the horizon, it will be important to establish baseline estimates of the burden of RSV infections in high-risk populations, like Native Americans, and to maintain surveillance post-licensure in order to evaluate impact. Native Americans are also at higher risk for severe respiratory infections associated with human metapneumovirus (HMPV) and other viruses, which will also be monitored through this system.